fenoterol was found to be associated with a higher risk of fatal or near-fatal asthma than was inhaled salbutamol (5) . A possible explanation put forth by the authors for this higher risk is the different dose, 200 /ig per inhalation for fenoterol versus 100 /xg for salbutamol, with 200 inhalations per canister for each /3 2 -agonist. The difference in risks disappeared when computed for equal doses, that is, assuming that each canister of fenoterol was equivalent to two canisters of salbutamol. This dose adjustment was criticized by some (6, 7) .
An alternative explanation suggested for the difference between the risk estimates was the preferential prescription of inhaled fenoterol to more severely afflicted asthmatics (8) (9) (10) (11) . The marketing of a higher dose formulation of greater potency for inhaled fenoterol as compared with salbutamol may have suggested that this drug was better suited to more severe asthmatics. As well, the introduction of inhaled fenoterol in 1978 after inhaled salbutamol, introduced in 1972, had obtained an important share of the market could have led patients who had initial therapy failure with inhaled salbutamol to be switched to inhaled fenoterol. Either mechanism would have given rise to confound-ing by indication of the comparison of the rates of asthma death and near-death between inhaled fenoterol and salbutamol. This phenomenon of selective prescribing of drugs from the same therapeutic class to patients with different prognostic characteristics or degrees of disease severity has been referred to as channeling (12) . It was investigated for /3-agonists using a cross-sectional design, arriving at different results in two studies (13, 14) . This design, however, is limited by its inability to discern directionality and to assess incidence of first use (15) .
In the present study, we use a longitudinal design to assess the channeling of /3 2 ' a g on i sts -Tim approach permits us to address two distinct mechanisms of this phenomenon leading to possible confounding by indication, namely, first use and subsequent switch of /3 2 -agonists. We assessed the determinants of a first prescription of inhaled fenoterol and salbutamol, the determinants of a switch from inhaled salbutamol to inhaled fenoterol, and the determinants of a switch from inhaled fenoterol to salbutamol. More specifically, we studied whether the level of severity and the extent to which the disease was kept under control were involved in the selection of one bronchodilator versus the other.
MATERIALS AND METHODS Source population
We conducted this study within the cohort of 12,301 asthmatics who were the object of the SAEP. This cohort, assembled from the computerized databases of Saskatchewan Health, has been described in detail previously (5) . Briefly, it is formed by all 12,301 members of the Saskatchewan Universal Prescription Drug Plan, aged between 5 and 54 years old, who had been dispensed at least 10 prescriptions of an asthma medication between January 1978 and April 1987. The medications in question were fenoterol, salbutamol, metaproterenol, terbutaline, theophylline, ipratropium bromide, sodium cromoglycate, and inhaled beclomethasone. The date of entry into the SAEP cohort was the latest of January 1, 1980, the date of the 10th prescription of an asthma medication, or the date of the fifth birthday. The SAEP cohort members were followed up until the earliest of the dates of death, of emigration from the province, of their 55th birthday, or April 31, 1987 .
Definition of the subcohorts and endpoints
To address the question of confounding by indication, we selected three subcohorts from the SAEP cohort of 12,301 asthmatics. The first subcohort, called the new use subcohort, comprises all 4,903 subjects who did not fill a prescription for either inhaled fenoterol or salbutamol for a minimum of 1 year before entry into the SAEP cohort. The selection process used to form the new use subcohort is summarized in table 1. The date of entry in the new use subcohort is the same as in the SAEP cohort. In this subcohort, the endpoints of interest are first use of inhaled fenoterol or first use of inhaled salbutamol. The subcohort members were then followed up until the earliest of the date of their first prescription of inhaled fenoterol, the date of their first prescription of inhaled salbutamol, or the end of the SAEP cohort follow-up. This subcohort was formed to study the determinants of the choice between inhaled fenoterol and salbutamol, when one of these bronchodilators was prescribed for the first time. 
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The second subcohort, called the SF subcohort, was formed to study the determinants of a first switch from inhaled salbutamol to inhaled fenoterol. It comprises the 8,945 subjects who had one or more dispensed prescriptions of inhaled salbutamol after entry into the SAEP cohort but were not prescribed inhaled fenoterol for a minimum of 1 year prior to this first prescription of inhaled salbutamol (see table 1 ). The entry date into the SF subcohort is the date of the first prescription of inhaled salbutamol after entry into the SAEP cohort. The endpoint of interest is a switch, defined by the first use of inhaled fenoterol. The subcohort members were thus followed until the earliest of their first prescription of inhaled fenoterol or the end of the SAEP cohort follow-up.
The third subcohort, called the FS subcohort, was formed to study the determinants of a first switch from inhaled fenoterol to inhaled salbutamol. This cohort is made up of the 658 subjects who had one or more dispensed prescriptions of inhaled fenoterol after entry into the SAEP cohort but were not prescribed inhaled salbutamol for a minimum of 1 year prior to this first prescription of inhaled fenoterol (see table 1 ). The entry date into the FS subcohort is the date of the first prescription of inhaled fenoterol after entry into the SAEP cohort. The endpoint of interest is a switch, defined by the first use of inhaled salbutamol. The subcohort members were thus followed until the earliest of their first prescription of inhaled salbutamol or the end of the SAEP cohort follow-up.
Determinants
The determinants of interest include recognized markers of asthma severity and disease control, other factors determining the choice of medication, and the age of the subject (5, (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Except for age, all determinants relate to dispensing of asthma medications or to the occurrence of asthma hospitalizations. The determinants were all defined in reference to the time of the endpoint of interest (index date), with different time-windows depending on the nature of the determinant.
The first marker of asthma severity was defined as the occurrence of one or more hospitalizations for asthma (International Classification of Diseases, Ninth Revision, code 493) in the 2-year time-window prior to the index date. A further five markers of asthma severity were based on the number of asthma prescriptions dispensed in the 3-month time-window prior to the index date. The four contrasts of interest were the following: 1) at least one prescription of an oral corticosteroid versus no prescription, 2) five or more prescriptions of inhaled salbutamol (>1.5 prescriptions/month) versus four prescriptions or less, 3) five or more prescriptions of inhaled fenoterol versus four prescriptions or less, 4) at least one prescription of an oral bronchodilator (oral /3-agonists and/or theophylline) versus no prescription, and 5) at least one prescription of a /3-agonist by nebulizer versus no prescription.
To define markers of disease control, we classified prescriptions for inhaled corticosteroids into two mutually exclusive time-windows: the 3-month and the 4-to 12-month periods prior to the index date. The division of this 12-month interval into these two time-windows allowed us to contrast long-term as opposed to more recent use only of inhaled corticosteroids.
The other three determinants were defined by the dispensing, or lack thereof, of other inhaled /3-agonists (metaproterenol and terbutaline), ipratropium bromide, and inhaled sodium cromoglycate in the 3-month time-window prior to the index date.
Statistical analysis
The analysis was performed using a case-control approach independently for each subcohort.
As usual with density sampling, the cases may have been selected as a control before their index date (28) . For every incident user of fenoterol (case) identified in the new use subcohort, we matched, by year of index date and year of entry into the subcohort, all available incident users of salbutamol (controls). For this analysis, the markers of severity and disease control were measured before the dispensing of the first prescription of inhaled fenoterol or salbutamol.
For each switcher (case) identified in the SF subcohort, we selected 10 nonusers of fenoterol (controls) matched by month of index date and month of subcohort entry. In the FS subcohort, we selected up to 30 controls for each case, and the controls were matched by month of index date and year of subcohort entry. In these two analyses, the switchers, who were incident users of inhaled fenoterol or salbutamol, were compared with prevalent users of the other j3 2 -agonist. We are therefore examining the determinants of a change in inhaled bronchodilator medication. In these two analyses, the markers of severity and disease control are measured before the first dispensed prescription of inhaled fenoterol or salbutamol for the cases and at the time-matched point during continuing therapy with the other ^-agonist for the controls.
Separate analyses were carried out for each subcohort using conditional logistic regression to estimate the crude and adjusted rate ratios for the determinants of interest (29) . Backward elimination was used to arrive at the most parsimonious model (30) .
RESULTS
New use subcohort
During the period of observation, 203 subjects among the 4,903 members of the new use subcohort received a first prescription of inhaled fenoterol before any prescription of inhaled salbutamol, 2,770 subjects received a first prescription of inhaled salbutamol before any prescription of inhaled fenoterol, and 21 subjects received a first prescription of these two medications within the same month. These 21 subjects were eliminated from the analysis, since they were concordant in their measure of the determinants. The case-control analysis consisted of 203 incident users of fenoterol (cases) and 2,717 matched incident users of salbutamol (controls). The number of controls per case varied from 10 to 315, and 53 incident users of salbutamol (representing less than 2 percent of all incident users of salbutamol in the new use subcohort) were excluded because they could not be matched to any of the cases. The exclusion of these 53 subjects allowed us to keep the matching intact in the analysis, which is essential to take into account the calendar time at which the first prescription of a /3 2 -agonist was dispensed. Table 2 provides the distribution of the determinants, as well as the crude and adjusted matched rate ratios (RRs) for the effect of the determinants on prescribing inhaled fenoterol versus inhaled salbutamol. Very few incident users of inhaled fenoterol or salbutamol, less than 6 percent, were dispensed /3-agonists by nebulizer, ipratropium bromide, or a corticosteroid, whether oral or inhaled, in the 3-month time-window prior to the index date. The adjusted estimates of the rate ratios were obtained from a conditional logistic model including all the determinants listed in table 2. The adjusted rate ratios were similar to the crude rate ratios, and none of the recognized markers of asthma severity or disease control was significantly related to being prescribed inhaled fenoterol or salbutamol. However, users of other inhaled /3-agonists and users of ipratropium bromide were almost two times and four times, respectively, more likely to be prescribed inhaled fenoterol rather than inhaled salbutamol. The most parsimonious model contained only other inhaled /3-agonists (RR = 1.9, 95 percent confidence interval (CI) 1.2-3.0), ipratropium bromide (RR = 4.1, 95 percent CI 1.2-14.4), and age at index date (RR = 1.2 per decade, 95 percent CI 1.1-1.3).
SF subcohort
Among the 8,945 members of the SF subcohort, 507 subjects switched from inhaled salbutamol to inhaled fenoterol. The case-control analysis is based upon these 507 switchers (cases) and a sample of 5,070 matched nonusers of inhaled fenoterol (controls). Table 3 presents the crude and adjusted matched rate ratios of the likelihood of switching from inhaled salbutamol to inhaled fenoterol, for the various determinants. The adjusted estimates of the rate ratios were obtained from a conditional logistic regression model including all the determinants listed in table 3 except past use of inhaled corticosteroids (4-to 12-month time-window). This determinant was not included in the full model, because it was an effect modifier of the effect of recent use of inhaled corticosteroids (3-month time-window) and is analyzed as such subsequently. The adjusted rate ratios were lower than the crude rate ratios, and the adjustment was particularly important for oral and inhaled corticosteroids. The five markers of severity were significantly associated with an increased probability of switching from inhaled salbutamol to inhaled fenoterol. Users of other inhaled /3-agonists and ipratropium bromide were also more likely to switch than were nonusers. It is worth noting that users of inhaled corticosteroids in the 3 months prior to the index date were less likely to switch to inhaled fenoterol than were nonusers. The most parsimonious model excluded /3-agonists by nebulizer, ipratropium bromide, and inhaled sodium cromoglycate.
To further investigate the effect of inhaled corticosteroids, we added to the most parsimonious model the use of inhaled corticosteroids in the 4-to 12-month time-window and an interaction term between the 3-month and the 4-to 12-month time-windows. This new model, presented in table 4, shows that long-term users of inhaled corticosteroids (individuals who received at least one prescription of inhaled corticosteroids in each of the two time-windows) had less than half the risk of switching to inhaled fenoterol than those who discontinued their treatment with that medication in the 3-month period prior to the index date (RR = 0.4, 95 percent CI 0.3-0.6). We also found that individuals who initiated a treatment with inhaled corticosteroids within 3 months prior to the index date (recent users) were 1.5 (95 percent CI 0.9-2.3) times more likely to switch to inhaled fenoterol than were individuals who did not use this medication for 1 year prior to the index date.
FS subcohort
Among the 658 members of the FS subcohort, 264 subjects switched from inhaled fenoterol to inhaled salbutamol. The analysis was based on these 264 cases and 7,812 matched controls. Between six and 30 controls were matched to each case in order to increase the precision of the estimates. Table 5 presents the crude and adjusted rate ratios of a switch from inhaled fenoterol to salbutamol for all the determinants. The adjusted estimates of the rate ratios were obtained from a conditional logistic regression model including all the determinants listed in table 5. The adjusted model shows that only the use of oral corticosteroids and the use of an oral bronchodilator in the 3 months preceding the index date were significantly associated with a switch. The most parsimonious model included the use of oral corticosteroids (RR = 1.4, 95 percent CI 1.1-2.0) and use of an oral bronchodilator (RR = 1.5, 95 percent CI 1.2-2.0).
DISCUSSION
In this study, we found that asthmatics with markers of greater severity or less well-controlled asthma were as likely to initiate a treatment with inhaled fenoterol as opposed to inhaled salbutamol. On the other hand, we found that users of inhaled salbutamol with markers of severe or less well-controlled asthma were more likely to be switched to inhaled fenoterol than were salbutamol users without these characteristics. We also found that the switch from inhaled fenoterol to inhaled salbutamol was less related to the severity and control of asthma than was the other switch, since only two markers of severity were associated with such a change in therapy. Although the common belief is that the fact of switching is in itself associated with increased severity of asthma (13, 14) , we found that more than the fact of switching, the direction of the switch was associated with asthma severity. In essence, it appears that, after 1980, the initial choice between inhaled fenoterol and salbutamol was independent of severity or the degree of control of asthma, whereas inhaled fenoterol was preferentially prescribed to users of inhaled salbutamol who showed signs of greater severity or less well-controlled asthma. This differential pattern of indication may result in bias in epidemiologic studies, particularly case-control studies, examining /3 2 -agonist use as a risk factor for adverse outcomes.
Using a cross-sectional design, Petri et al. (13) found that, among asthmatics aged between 5 and 45 years, more than 20 percent of users of inhaled fenoterol were also using oral corticosteroids as comedication, whereas less than 10 percent of users of inhaled salbutamol were using such co-medication. Users of inhaled fenoterol were also taking more other antiasthma drugs than were users of inhaled salbutamol. The authors concluded that Dutch physicians were more prone to channel fenoterol to patients with In this  table. t CI, confidence Interval. t Long-term use is defined as one or more dispensed prescriptions of Inhaled corticosteroids in the 3-month and 4-to 12-month time windows. Discontinued use is defined as one or more dispensed prescriptions of Inhaled corttcosterokls in the 4-to 12-month time window and no use of that medication in the 3-month time window.
§ Recent use Is defined as one or more dispensed prescriptions of Inhaled corticosteroids In the 3-month time window, and no use refers to no use of that medication In the 12 months prior to the index date.
II The rate ratio for age at index date is given per decade.
more severe forms of asthma. Also, using a crosssectional approach, Beasley et al. (14) investigated the presence of preferential prescribing of fenoterol versus salbutamol among prevalent users of these two medications and the effect of asthma severity on the likelihood of switching from one /3 2 -agonist to the other. They concluded that, in New Zealand, fenoterol was not preferentially prescribed to patients with more severe asthma. The cross-sectional design of these two studies did not permit distinguishing between the two forms of channeling, i.e., first use of a /3 2 -agonist and a first switch from one product to the other. Our longitudinal approach permits the study of these two forms of channeling. The underlying objective of the present study was to assess whether the comparison of the rate ratios for inhaled fenoterol and salbutamol found in the SAEP was confounded by indication. In the SAEP nested case-control study, exposure to the /3 2 -agonist was assessed within a fixed time-window of 1 year anchored at the time of asthma death or near death for the cases and the matching index date for the controls. The study subjects were considered as exposed to inhaled fenoterol or salbutamol if they received at least one prescription of either medication within the previous year and if the exposure that took place prior to the 1-year time-window was not ascertained. Based on the data available in this nested case-control study, the proportion of current users of inhaled fenoterol who had previously used inhaled salbutamol is impossible to know exactly. However, we can assume that a significant proportion of the current users of inhaled fenoterol in the SAEP were previously using inhaled salbutamol since, in the present analysis, approximately 70 percent of the incident users of inhaled fenoterol had been switched from inhaled salbutamol to fenoterol. On the other hand, only 9 percent of the incident users of inhaled salbutamol had used inhaled fenoterol in the past. These results lead us to conclude that the comparison between inhaled fenoterol and salbutamol in the SAEP may have been biased because of confounding by indication.
Additional results presented in this paper are worthy of discussion. In the new use subcohort, none of the proposed markers of severity or control of asthma were found to be statistically significant, whereas users of ipratropium bromide and other inhaled /3-agonists were, respectively, 3.9 and 1.9 times more likely to initiate a treatment with fenoterol rather than salbutamol. These results may be explained by the fact that ipratropium bromide and inhaled metaproterenol, which represent more than 70 percent of the prescriptions regrouped under the variable labeled "other inhaled /3-agonists," are manufactured by the same pharmaceutical company as fenoterol. A possible explanation is that the physicians could have been more prone to prescribe inhaled fenoterol to their patients who were already treated with a medication that was manufactured by the same company and therefore marketed through the same representatives.
The rate ratios found for inhaled corticosteroids in the SF subcohort confirmed the results found in other studies (24, 31, 32 ) that long-term use of this medication is associated with better control of asthma. We showed that long-term users of inhaled corticosteroids were less likely to require a change of their inhaled /3 2 -agonist. On the other hand, recent initiation of a treatment with inhaled corticosteroids, which may be deemed to indicate a need for control, was found to be associated with an increased likelihood of a switch from inhaled salbutamol to inhaled fenoterol.
The analyses presented in this article focused on the study of incident users of inhaled ^-agonists. This represents 49 percent of users of inhaled fenoterol and 31 percent of users of inhaled salbutamol in the SAEP cohort. The other 51 and 69 percent are subjects who were prevalent users of either inhaled fenoterol or salbutamol, because they had received at least one prescription of either of these medications before entry into the SAEP cohort. Further research is needed to determine whether channeling between inhaled fenoterol and salbutamol is more or less pronounced when they are used as first line therapy.
The validity of the present study depends, in large part, on the capacity of the studied determinants to accurately reflect important aspects of the severity and control of asthma. The markers of severity and disease control that we considered were selected because they have been shown, in previous studies, to be associated with fatal or near fatal asthma (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) or because they were recognized as such by the current guidelines for the management of asthma (16, 17) . We have to keep in mind, however, that the studied markers of severity and disease control were based on computerized data and that no physiologic measures of asthma severity and disease control were available for consideration in the models. The validity of the results is also contingent upon the quality of the data coming from the Saskatchewan Health databases. These administrative databases are used by the Health Ministry to manage the reimbursement of medications to pharmacies. To ensure the quality of the data and to allow their use for research purposes, a series of checks are made on each prescription submitted for reimbursement, and a random sample of reimbursed prescriptions is selected every week for validation and confirmation with the beneficiary (33) (34) (35) . The data, however, represent dispensed prescriptions and may therefore not correspond exactly to the medications actually taken. This may have led to nondifferential misclassification of the exposure, thus causing an underestimation of the rate ratios (36) .
In conclusion, this study showed that the indication, in terms of severity and control of asthma, for use of inhaled fenoterol may change over the course of disease and depends on previous use of /3 2 -agonists. Although the initial choice between inhaled fenoterol and salbutamol appears to have been independent of the severity of disease, preferential prescribing of inhaled fenoterol seems to have occurred among users of inhaled salbutamol who showed signs of greater severity or less well-controlled asthma. The switch from inhaled fenoterol to inhaled salbutamol was only minimally related to the severity and the control of asthma, however. This may have resulted from the perception among prescribers and patients that fenoterol was a more potent bronchodilator. A change to this medication would therefore frequently occur in response to a worsening of symptoms, whereas a more appropriate and effective strategy would have been the initiation or increase in preventive and antiinflammatory treatment strategies (17, 37) . This study thus demonstrates that a longitudinal design is essential when investigating the presence of channeling and that two forms of channeling must be distinguished: initial use and switching. As well, the direction and not only the fact of a switch must be considered. It also demonstrates that "current use" may be an inappropriate measure of exposure in case-control studies of asthma and possibly other diseases. Long-term information on medication use is needed to ensure that the resulting rate ratio comparing the effect of two medications is not biased by indication. This implies that, in casecontrol studies, die time-window used to ascertain the exposure to the medications of interest should be of sufficient length to cover the complete history of medication use and perhaps even a period of observation before initiation of the therapies under study.
